Literature DB >> 30587494

A second-generation TKI should always be used as initial therapy for CML.

Jorge E Cortes1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30587494      PMCID： PMC6306878          DOI： 10.1182/bloodadvances.2018018655

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  19 in total

1.  Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.

Authors:  Andreas Hochhaus; Richard A Larson; François Guilhot; Jerald P Radich; Susan Branford; Timothy P Hughes; Michele Baccarani; Michael W Deininger; Francisco Cervantes; Satoko Fujihara; Christine-Elke Ortmann; Hans D Menssen; Hagop Kantarjian; Stephen G O'Brien; Brian J Druker
Journal:  N Engl J Med       Date:  2017-03-09       Impact factor: 91.245

2.  Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib.

Authors:  Jorge E Cortes; H Jean Khoury; Hagop Kantarjian; Tim H Brümmendorf; Michael J Mauro; Ewa Matczak; Dmitri Pavlov; Jean M Aguiar; Kolette D Fly; Svetoslav Dimitrov; Eric Leip; Mark Shapiro; Jeff H Lipton; Jean-Bernard Durand; Carlo Gambacorti-Passerini
Journal:  Am J Hematol       Date:  2016-04-13       Impact factor: 10.047

3.  Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience.

Authors:  Ohad Benjamini; Hagop Kantarjian; Mary Beth Rios; Elias Jabbour; Susan O'Brien; Preetesh Jain; Marylou Cardenas-Turanzas; Stefan Faderl; Guillermo Garcia-Manero; Farhad Ravandi; Gautam Borthakur; Alfonso Quintas-Cardama; Jorge Cortes
Journal:  Leuk Lymphoma       Date:  2013-09-10

4.  Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.

Authors:  Hugues de Lavallade; Jane F Apperley; Jamshid S Khorashad; Dragana Milojkovic; Alistair G Reid; Marco Bua; Richard Szydlo; Eduardo Olavarria; Jaspal Kaeda; John M Goldman; David Marin
Journal:  J Clin Oncol       Date:  2008-06-02       Impact factor: 44.544

5.  Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.

Authors:  Koji Sasaki; Sara S Strom; Susan O'Brien; Elias Jabbour; Farhad Ravandi; Marina Konopleva; Gautam Borthakur; Naveen Pemmaraju; Naval Daver; Preetesh Jain; Sherry Pierce; Hagop Kantarjian; Jorge E Cortes
Journal:  Lancet Haematol       Date:  2015-04-20       Impact factor: 18.959

6.  Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.

Authors:  Jorge E Cortes; Carlo Gambacorti-Passerini; Michael W Deininger; Michael J Mauro; Charles Chuah; Dong-Wook Kim; Irina Dyagil; Nataliia Glushko; Dragana Milojkovic; Philipp le Coutre; Valentin Garcia-Gutierrez; Laurence Reilly; Allison Jeynes-Ellis; Eric Leip; Nathalie Bardy-Bouxin; Andreas Hochhaus; Tim H Brümmendorf
Journal:  J Clin Oncol       Date:  2017-11-01       Impact factor: 50.717

7.  Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors.

Authors:  Lorenzo Falchi; Hagop M Kantarjian; Xuemei Wang; Dushyant Verma; Alfonso Quintás-Cardama; Susan O'Brien; Elias J Jabbour; Farhad Ravandi-Kashani; Gautam Borthakur; Guillermo Garcia-Manero; Srdan Verstovsek; Jan A Burger; Raja Luthra; Jorge E Cortes
Journal:  Am J Hematol       Date:  2013-09-12       Impact factor: 10.047

Review 8.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Authors:  Michele Baccarani; Michael W Deininger; Gianantonio Rosti; Andreas Hochhaus; Simona Soverini; Jane F Apperley; Francisco Cervantes; Richard E Clark; Jorge E Cortes; François Guilhot; Henrik Hjorth-Hansen; Timothy P Hughes; Hagop M Kantarjian; Dong-Wook Kim; Richard A Larson; Jeffrey H Lipton; François-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Fabrizio Pane; Jerald P Radich; Philippe Rousselot; Giuseppe Saglio; Susanne Saußele; Charles Schiffer; Richard Silver; Bengt Simonsson; Juan-Luis Steegmann; John M Goldman; Rüdiger Hehlmann
Journal:  Blood       Date:  2013-06-26       Impact factor: 22.113

9.  Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities.

Authors:  Preetesh Jain; Hagop Kantarjian; Aziz Nazha; Susan O'Brien; Elias Jabbour; Carlos Guillermo Romo; Sherry Pierce; Marylou Cardenas-Turanzas; Srdan Verstovsek; Gautam Borthakur; Farhad Ravandi; Alfonso Quintás-Cardama; Jorge Cortes
Journal:  Blood       Date:  2013-04-25       Impact factor: 22.113

10.  Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.

Authors:  Tim H Brümmendorf; Jorge E Cortes; Cármino Antonio de Souza; Francois Guilhot; Ladan Duvillié; Dmitri Pavlov; Karïn Gogat; Athena M Countouriotis; Carlo Gambacorti-Passerini
Journal:  Br J Haematol       Date:  2014-09-08       Impact factor: 6.998
View more
  2 in total

1.  Long-Term Survival, Vascular Occlusive Events and Efficacy Biomarkers of First-Line Treatment of CML: A Meta-Analysis.

Authors:  Hélène Haguet; Carlos Graux; François Mullier; Jean-Michel Dogné; Jonathan Douxfils
Journal:  Cancers (Basel)       Date:  2020-05-15       Impact factor: 6.639

2.  Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States.

Authors:  Rory M Shallis; Rong Wang; Jan P Bewersdorf; Amer M Zeidan; Amy J Davidoff; Scott F Huntington; Nikolai A Podoltsev; Xiaomei Ma
Journal:  Ther Adv Hematol       Date:  2021-11-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.